PASQUINUCCI, Lorella Giuseppina
 Distribuzione geografica
Continente #
NA - Nord America 6.861
EU - Europa 2.473
AS - Asia 2.146
AF - Africa 467
SA - Sud America 408
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 1
Totale 12.366
Nazione #
US - Stati Uniti d'America 6.693
IT - Italia 1.177
SG - Singapore 918
CN - Cina 853
IE - Irlanda 415
BR - Brasile 361
CI - Costa d'Avorio 311
UA - Ucraina 278
DE - Germania 167
CA - Canada 144
SN - Senegal 119
RU - Federazione Russa 118
KR - Corea 117
JP - Giappone 47
FR - Francia 44
GB - Regno Unito 39
ES - Italia 38
IN - India 38
VN - Vietnam 37
FI - Finlandia 34
SE - Svezia 34
NL - Olanda 25
ID - Indonesia 24
BE - Belgio 21
BD - Bangladesh 20
PL - Polonia 19
HK - Hong Kong 16
AT - Austria 14
MX - Messico 14
TR - Turchia 14
AR - Argentina 13
CH - Svizzera 11
UZ - Uzbekistan 11
ZA - Sudafrica 11
AU - Australia 10
CZ - Repubblica Ceca 10
EC - Ecuador 10
IR - Iran 9
GR - Grecia 8
IQ - Iraq 8
HU - Ungheria 7
PK - Pakistan 7
VE - Venezuela 7
AE - Emirati Arabi Uniti 6
CO - Colombia 6
TN - Tunisia 6
LB - Libano 5
MA - Marocco 5
BG - Bulgaria 4
KE - Kenya 4
NG - Nigeria 4
SA - Arabia Saudita 4
CL - Cile 3
DZ - Algeria 3
EG - Egitto 3
IL - Israele 3
JM - Giamaica 3
KZ - Kazakistan 3
PE - Perù 3
RS - Serbia 3
BB - Barbados 2
DO - Repubblica Dominicana 2
GE - Georgia 2
LT - Lituania 2
NP - Nepal 2
PY - Paraguay 2
UY - Uruguay 2
AL - Albania 1
AZ - Azerbaigian 1
BO - Bolivia 1
CR - Costa Rica 1
DK - Danimarca 1
EU - Europa 1
IM - Isola di Man 1
NO - Norvegia 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
SL - Sierra Leone 1
TT - Trinidad e Tobago 1
Totale 12.366
Città #
Dallas 2.244
Santa Clara 774
Chandler 591
Singapore 546
Houston 471
Dublin 412
Catania 356
Chicago 334
Abidjan 311
Jacksonville 286
Hefei 230
Ashburn 212
Boardman 188
Dakar 119
Seoul 117
Nanjing 116
Cambridge 110
Andover 109
Lawrence 109
Beijing 107
Civitanova Marche 98
Toronto 95
Council Bluffs 62
Bremen 60
Wilmington 57
Rome 54
Des Moines 50
San Mateo 47
The Dalles 45
Los Angeles 40
Tokyo 40
Columbus 39
Naples 38
Grafing 36
Munich 35
Shenyang 35
Nanchang 33
Saint Petersburg 32
São Paulo 30
Changsha 26
New York 26
Jiaxing 25
Ottawa 25
Messina 24
Hebei 21
Brussels 20
Tianjin 19
Jakarta 17
Milan 17
Moscow 17
Pune 17
Rio de Janeiro 17
Falls Church 15
Hong Kong 14
San Giovanni la Punta 14
Turku 14
Seattle 13
San Francisco 12
Dong Ket 11
Helsinki 11
Augusta 10
Brooklyn 10
Ho Chi Minh City 10
Ningbo 10
Norwalk 10
Pozzallo 10
Warsaw 10
Jinan 9
Lappeenranta 9
Madrid 9
Palermo 9
Rimini 9
Sala Baganza 9
Salerno 9
Ardabil 8
Bari 8
Belo Horizonte 8
Bologna 8
Leawood 8
Montreal 8
Paris 8
Paternò 8
Amsterdam 7
Brno 7
Budapest 7
Hanoi 7
Marseille 7
Melbourne 7
Monmouth Junction 7
Tappahannock 7
Tashkent 7
Washington 7
Atlanta 6
Cagliari 6
Dearborn 6
Den Haag 6
Fukuoka 6
Gravina di Catania 6
Guangzhou 6
Lentini 6
Totale 9.358
Nome #
From Plant to Chemistry: Sources of Active Opioid Antinociceptive Principles for Medicinal Chemistry and Drug Design 430
Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation 390
Targeting histone deacetylase 1: Inhibition and activation as promising therapeutic strategies for diverse disorders 384
((2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist 265
The simultaneous activation of μ- and δ-opioid receptors by (−)-2S-LP2 rescues allodynia with the contribution of TGF-β1 signaling in a rat chronic constriction injury model 184
Do vitamins halt the COVID-19-evoked pro-inflammatory cytokines involved in the development of neuropathic pain? 164
Antioxidant properties and pharmacokinetic studies of new selective σ1 bifunctional ligands 154
Neuroprotective effects of Rosmarinus officinalis L. extract in oxygen glucose deprivation (OGD)-injured human neural-like cells 154
Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands 148
Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells 147
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects 132
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti 131
A new Sigma-1 Receptor antagonist in Chronic Pain Treatment: (+)-2R/S-LP2 effects in inflammatory and neuropathic pain 124
Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review 123
Caspase-3 activation in human melanoma A375 cell line by a novel selective sigma-2 agonist 122
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 120
R- ed S-LP2: sintesi, molecular docking e valutazione farmacologica 117
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 112
Design of Small Molecules for Oncological and Neurodegenerative Diseases 111
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma 110
Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand. 107
(+)-cis-N-ethyleneamino-N-normetazocine derivatives. Novel and selective sigma ligands with antagonist properties 106
ANTIALLODINIC AND ANTIHYPERALGESIC EFFECTS OF LP1, AN OPIOID MULTITARGET LIGAND, IN INFLAMMATORY AND NEUROPATHIC PAIN STATES 105
LP2 e 2S-LP2: agonisti biased dual target MOR/DOR nel trattamento del dolore cronico 105
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists 103
From plant to bench: natural products as source for analgesic drug development. 103
Intercellular communication and ion channels in neuropathic pain chronicization 103
The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling 102
Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review 99
In Vitro Antioxidant Activity and In Vivo Topical Efficacy of Lipid Nanoparticles Co-Loading Idebenone and Tocopheryl Acetate 99
Development of novel LP1-based analogues with enhanced delta opioid receptor profile 98
Benzomorphan-based opioid ligands with mixed m agonist/d antagonist activity 97
Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation 97
Analgesici oppioidi: nuove opportunità nella terapia del dolore 96
CCB, a novel specific kappa opioid agonist, which discriminates between opioid and sigma 1 recognition sites 96
Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands 95
Bivalent opioid-peptides synthesized from mu-selective monomers display preferential selectivity for delta-receptors 95
The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammation. 94
Bivalent opioid peptides synthesized from μ selective monomers display preferential selectivity for δ receptors 93
Sigma-1 Receptor Inhibition Reduces Mechanical Allodynia and Modulate Neuroinflammation in Chronic Neuropathic Pain 91
The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment 91
Mu and Delta Opioid Receptor Targeting Reduces Connexin 43-Based Heterocellular Coupling during Neuropathic Pain 90
Dual MOR/DOR agonist benzomorphan-based compounds for pain relief 90
Multitarget opioid ligands in pain relief: New players in an old game 89
SYNTHESIS OF (+)-(1'R,2'S) AND (1'S,2'R)-6,11-DIMETHYL-1,2,3,4,5,6-HEXAHYDRO-3-[[2'-(ALKOXYCARBONYL)-2'-PHENYLCYCLOPROPYL]METHYL]-2,6-METHANO-3-BENZAZOCIN-8-OL. COMPARISON OF THE AFFINITIES FOR SIGMA 1 AND OPIOID RECEPTORS WITHIN THE DIASTEREOISOMERIC MPCB AND CCB 88
CCB - A novel analog of MPCB with high binding affinity and specific kappa opioid receptor agonist 88
Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 88
Design, synthesis, and biological evaluation of new hybrid MOR agonist/HDACi compounds: an innovative approach for persistent pain management 87
An LP1 analogue, selective MOR agonist with a peculiar pharmacological profile, used to scrutiny the ligand binding domain 87
MOR/DOR targeting: an useful strategy in pain management 87
Design and synthesis of trans-decahydroisoquinoline derivatives as new tramadol-like ligands 86
Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management 86
Non-peptide ligands for opioid receptors. Design of kappa-specific agonists 85
The benzomorphan-based compound LP1 is a central acting MOR agonist/DOR antagonist suitable for chronic pain treatment 85
A New LP1 analogue is used to better understand MOR ligand Binding Domain and its mechanisms of activation 85
Evaluation of N-substituent structural variations in opioid receptor profile of LP1. 85
Substituted 1-phenyl-2-cyclopropylmethylamines with high affinity and selectivity for sigma sites 85
Nonpeptide Analogues of Dynorphin A(1-8): Design, Synthesis, and Pharmacological Evaluation of k-Selective Agonists 84
The Benzomorphan-Based Compound LP1 as Suitable Candidate for Pain Management 84
Antiallodinic and antihyperalgesic effects of LP1, an opioid multitarget ligand, in inflammatory and neurophatic pain states 82
Simultaneous Activation of Mu and Delta Opioid Receptors Reduces Allodynia and Astrocytic Connexin 43 in an Animal Model of Neuropathic Pain 82
Discovery of first novel sigma/HDACi dual-ligands with a potent in vitro antiproliferative activity 79
In vitro and in vivo pharmacological evaluation of LP1, a benzomorphan-based compound 79
Rosemary Essential Oil-Loaded Lipid Nanoparticles: In Vivo Topical Activity from Gel Vehicles 79
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics in Inflammatory Pain 78
Differential scanning calorimetry approach to investigate the transfer of the multitarget opioid analgesic LP1 to biomembrane model 78
Progress in the development of more effective and safer analgesics for pain management 78
Multitarget opioid ligands as suitable candidates for pain management Pharmacolgical fingerprint of the benzomorphan-based opioid compound LP1 77
Analoghi non-peptidici della dinorfina A(1-8): progettazione, sintesi e valutazione farmacologica di agonisti ad elevata selettività Kappa. 76
Analgesici oppioidi 75
New Insights into the Opioid Analgesic Profile of cis-(-)-N-Normetazocine-derived Ligands 74
THE BENZOMORPHAN-BASED COMPOUND LP1 AS A MULTITARGET OPIOID LIGAND FOR CHRONIC PAIN TREATMENT 74
From agonist to antagonist profile in LP1 analogues through the introduction of different N-substituents in benzomorphan-based ligands 74
New developments in opioid receptors ligands 73
The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures 73
The blockade of NOP receptor in the vlPAG reduces the development of tolerance to opioid-induced antinociception in rats 72
In-vitro evaluation of a new benzomorphan-based ligand 72
Synthesis and structure-activity relationships of (–)-cis-N-normetazocine-based LP1 derivatives 72
From Plant to Chemistry: Sources of Antinociceptive Non-Opioid Active Principles for Medicinal Chemistry and Drug Design 71
Correction to Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 71
Idebenone: Novel strategies to improve its systemic and local efficacy 71
Synthesis and in vitro opioid receptor studies on benzomorphan-based compounds: LP1, a potent and long-acting antinociceptive 70
Designing drugs optimized for both blood-brain barrier permeation and intra-cerebral partition 69
Synthesis, Computational Insights, and Evaluation of Novel Sigma Receptors Ligands 69
Novel methyl-2-[4-[(4-hydroxy-4-phenylpiperidin-1-yl)methyl]-1-phenylcyclopropane-carboxylate derivatives as sigma-1 and sigma-2 receptor ligands 69
Development of new benzomorphan LP1 analogues 69
New benzomorphan derivatives of MPCB as MOP and KOP receptor ligands 69
Design, Synthesis and biological evaluation of hybrid MOR agonist/ HDACi molecules as potential therapeutic agents for chronic pain treatment 68
Synthesis and Pharmacological Evaluation of Peptidomimetic of the Kappa-Opioid Receptors 68
Opioid multiple ligands 68
Resveratrol-loaded lipid nanocarriers: Correlation between in vitro occlusion factor and in vivo skin hydrating effect 68
Hybrid MOR agonist/HDACi molecules as potential antinociceptive multi-target drugs: design, synthesis, and biological evaluation 67
Dual-target ligands and pain: our experience 66
Modulation of opioid receptor profile of LP1 analogues through the introduction of different N-substituents 66
Specific kappa opioid receptor agonists 66
New bifunctional antioxidant/σ1 agonist ligands: preliminary chemico-physical and biological evaluation 65
Evaluation of N-substitution in 6,7-benzomorphan compounds 65
Synthesis of substituted pyrimidines, pyrazole[3,4-d]pyrimidines and imidazo[4,5-d]pyrimidines and evaluation of their antifungal activity 65
Simultaneous activation of mu and delta opioid receptors reduces allodynia and astrocytic connexin 43 in an animal model of neuropathic pain 65
Design, synthesis and biological evaluation of MOR agonist/HDACi hybrid compounds: a new potential therapeutic strategy for persistent pain management 64
Totale 10.192
Categoria #
all - tutte 40.166
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.166


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021520 0 0 0 18 167 18 64 6 85 13 114 35
2021/2022934 100 105 9 24 135 11 120 34 84 26 36 250
2022/20231.774 140 97 29 239 132 267 6 344 365 35 80 40
2023/20241.092 55 138 51 40 56 262 67 111 8 30 188 86
2024/20253.397 83 520 150 227 665 426 231 137 219 263 226 250
2025/20263.437 473 387 2.483 94 0 0 0 0 0 0 0 0
Totale 12.704